Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Quinupristin-Dalfopristin.

Linden1

  • 1University of Pittsburgh Medical Center, Division of Critical Care Medicine, Scaife Hall, Room 638, 200 Lothrop Street, Pittsburgh, PA 15213, USA.

Current Infectious Disease Reports
|November 30, 2000
PubMed
Summary

Multidrug-resistant gram-positive infections are a growing threat. Quinupristin-dalfopristin offers a novel treatment option with proven efficacy against challenging bacterial strains.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IL-17 as a potential target for modulating airway neutrophilia.

Current pharmaceutical design·2002
Same author

Camphor-based alpha-bromo ketones for the asymmetric darzens reaction

The Journal of organic chemistry·2001
Same author

Oligosaccharides potentiate methyl jasmonate-induced production of paclitaxel in Taxus canadensis.

Plant science : an international journal of experimental plant biology·2000
Same author

Polynuclear chloromercurate(II) systems in their chloropyridinium salts.

Acta crystallographica. Section B, Structural science·2000
Same author

(+/-)-9-(2-bromophenyl)-7,7-dimethyl-1,3,4,5,6,7,8,9-octahydrofuro

Acta crystallographica. Section C, Crystal structure communications·2000
Same author

alpha-Oxymethyl Ketone Enolates for the Asymmetric Mannich Reaction. From Acetylene and N-Alkoxycarbonylimines to beta-Amino Acids This work was supported by the University of the Basque Country, the Basque Government (Projects UPV 170.215-G47/98, EX-1998-124) and in part by M. E. C. (Project PB 98-0549). Grants to A.S. and M.C.G. from the Basque Government, and to C.L. from the Government of Navarra and M.E.C. are acknowledged.

Angewandte Chemie (International ed. in English)·2000

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Rising incidence of multidrug-resistant (MDR) and pan-resistant gram-positive bacterial infections.
  • Limited conventional antimicrobial options for treating these serious infections.
  • Need for novel therapeutic agents with distinct mechanisms of action.

Purpose of the Study:

  • To review the mechanism of action, spectrum of activity, clinical efficacy, and toxicity of quinupristin-dalfopristin.
  • To evaluate the potential role of quinupristin-dalfopristin in managing serious gram-positive infections.
  • To highlight quinupristin-dalfopristin's lack of cross-resistance with other antimicrobials.

Main Methods:

  • Literature review of studies on quinupristin-dalfopristin.
  • Analysis of in vitro data regarding antimicrobial spectrum.
  • Examination of clinical trial results for efficacy and safety.

Main Results:

  • Quinupristin-dalfopristin demonstrates potent in vitro activity against a range of MDR gram-positive pathogens.
  • Clinical studies show significant efficacy in treating serious infections caused by susceptible bacteria.
  • The drug exhibits a favorable safety profile with manageable toxicity.

Conclusions:

  • Quinupristin-dalfopristin is a valuable therapeutic option for infections caused by resistant gram-positive bacteria.
  • Its unique mechanism and lack of cross-resistance make it crucial for combating antimicrobial resistance.
  • Further research and clinical application are warranted to optimize its use in critical care settings.

Related Experiment Videos